Nevertheless, the mood on the call was rosey, as the continuing loss from Stelara was buffered by growth in almost every other area of the company\u2019s portfolio.<\/p>\n
<\/p>\n <\/a><\/p>\n \n The company cut back in areas while investing in internal and external opportunities to offset the loss of exclusivity on a product that until recently accounted for 20% of innovative medicine sales.\n <\/p>\n October 22, 2025<\/p>\n \u00a0\u00b7\u00a0<\/p>\n 5 min read<\/p>\n \u00a0\u00b7\u00a0<\/p>\n J&J now expects 2026 sales to reach $100.5 billion, 1.6% above consensus of $98.9 billion, according to CFO Joseph Wolk. He pointed to growing sales for franchises like dermatitis treatment Tremfaya, which rose from $3.6 billion in 2024 to $5.2 billion in 2025, as well as depression treatment Spravato, which improved from $1.1 billion to $1.7 billion.<\/p>\n The esketamine spray should be a cornerstone seller for the company, analysts at Jefferies wrote ahead of the call, saying that guidance for its sales out to 2027\u20132028 are set at $3 billion to $3.5 billion.<\/p>\n The analysts added that they see \u201ca warming regulatory environment\u201d for psychedelic-related treatments like Spravato in other indications, including anxiety and post-traumatic stress disorder.<\/p>\n J&J\u2019s oncology portfolio drove most of the growth, however, going from $20 billion across all drugs to $25 billion year-over-year, driven by sales for anti-tumor antibody Darzalex and CAR T treatment Carvykti, which crossed into blockbuster status for the first time with $1.8 billion in 2025 sales.<\/p>\n J&J mostly breezed past the impacts of regulatory headwinds coming from Washington, D.C. Wolk noted that potential tariffs affecting its medical technologies division amounted to approximately $500 million, significantly above 2025 levies, but said, \u201cour financial strength is a competitive advantage that allows us to both invest in our future and return value to our shareholders.\u201d<\/p>\n Wolk also added that the company expects that tariffs \u201cwill be relatively linear in 2026, unlike last year.\u201d<\/p>\n On the subject of the company\u2019s continuing litigation into its talc product<\/a>, which has been dogging the company for years as plaintiffs say the discontinued product is linked to ovarian and cervical cancers, company executives stood firm.<\/p>\n![\"Man](\"https:\/\/www.newsbeep.com\/nz\/wp-content\/uploads\/2026\/01\/1769328135_415_.jpeg\")
<\/p>\n
![\"Lawyers](\"https:\/\/www.newsbeep.com\/nz\/wp-content\/uploads\/2026\/01\/1769328135_581_.jpeg\")
<\/p>\n